References
- Apokyn (package insert) Morristown, NJ: Vernalis Pharmaceuticals Inc 2006
- Auffret, M., Drapier, S., & Vérin, M. (2018). Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance. Clinical Drug Investigation, 38(4), 287-312. doi:10.1007/s40261-018-0619-3
- Benarroch, E. E. (2014). The clinical approach to autonomic failure in neurological disorders. Nature Reviews Neurology, 10(7), 396-407. doi:10.1038/nrneurol.2014.88
- Bhidayasiri, R., Garcia Ruiz, P. J., & Henriksen, T. (2016). Practical management of adverse events related to apomorphine therapy. Parkinsonism and Related Disorders, 33, S42-S48. doi:10.1016/j.parkreldis.2016.11.017
- Bhidayasiri, R., Sringean, J., Anan, C., Boonpang, K., Thanawattano, C., & Ray Chaudhuri, K. (2016). Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson’s disease using wearable sensors. Parkinsonism & Related Disorders, 33 Suppl 1, S36-S41. doi:https://dx.doi.org/10.1016/j.parkreldis.2016.11.016
- Borgemeester, R. W. K., Drent, M., & van Laar, T. (2015). Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism and Related Disorders, 23, 17-22. doi:10.1016/j.parkreldis.2015.11.013
- Borgemeester, R. W. K., & van Laar, T. (2017). Continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with cognitive dysfunction: A retrospective long-term follow-up study. Parkinsonism and Related Disorders, 45, 33-38. doi:10.1016/j.parkreldis.2017.09.025
- Borovac, J. A. (2016). Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. (89), 37-47.
- Bowron, A. (2004). Practical considerations in the use of apomorphine injectable. Neurology, 62(6), S32-36.
- Buffery, P. J., & Strother, R. M. (2015). Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. The New Zealand medical journal, 128(1416), 66-74.
- Australian injectable drugs handbook (7th edition), (2016).
- Deloitte Access Economics. (2011). Living with Parkinson’s Disease - update (commissioned by Parkinson’s Australia). Retrieved from https://www2.deloitte.com/au/en/pages/economics/articles/living-with-parkinsons-disease.html
- Djamshidian, A., & Poewe, W. (2016). Apomorphine and levodopa in Parkinson’s disease: Two revolutionary drugs from the 1950’s. Parkinsonism and Related Disorders, 33, S9-S12. doi:10.1016/j.parkreldis.2016.12.004
- EPHPP (2010). Quality assessment tool for quantitative studies. The Effective Public Health Practice Project. http://www.ephpp.ca/PDF/Quality%20Assessment
- Grandas, F. (2013). Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease. 13, 1343-1353. doi:10.1586/14737175.2013.839235
- Gunzler, S. A. (2009). Apomorphine in the treatment of Parkinson disease and other movement disorders. Expert Opin Pharmacother, 10(6), 1027-1038. doi:10.1517/14656560902828344
- Hauser, R. A., Isaacson, S., & Clinch, T. (2014). Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism and Related Disorders, 20 (11), 1171-1176. doi:10.1016/j.parkreldis.2014.08.010
- Henriksen, T. (2014). Clinical insights into use of apomorphine in Parkinson’s disease: tools for clinicians. Neurodegenerative disease management, 4(3), 271-282. doi:10.2217/nmt.14.17
- Isaacson, S. H. (2016). Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia. Movement Disorders, 31(s2), S680-S680.
- Jellinger, K. (2015). Neuropathobiology of non-motor symptoms in Parkinson disease. Journal of Neural Transmission, 122(10), 1429-1440. doi:10.1007/s00702-015-1405-5
- Kaminioti, A. N., Nikitas, G. T., Terlis, A. K., Manolis, A. G., Thomaides, T., & Panousopoulou, A. N. (2013). Ventricular bigeminy after subcutaneous administration of apomorphine in a patient with refractory Parkinson’s disease: a case report. Journal of movement disorders, 6(1), 9. doi:10.14802/jmd.13002
- Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, K. R., … Lees, A. (2018). Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurology, 17(9), 749-759. doi:10.1016/S1474-4422(18)30239-4
- Lertxundi, U., Domingo-Echaburu, S., Soraluce, A., Garcia, M., Ruiz-Osante, B., & Aguirre, C. (2013). Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf, 8(1), 63-68.
- LeWitt, P. A., Ondo, W. G., Van Lunen, B., & Bottini, P. B. (2009). Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clinical neuropharmacology, 32 (2), 89-93. doi:https://dx.doi.org/10.1097/WNF.0B013E31816D91F9
- Menon, R., & Stacy, M. (2007). Apomorphine in the treatment of Parkinson’s disease. Expert opinion on pharmacotherapy, 8(12), 1941-1950. doi:10.1517/14656566.8.12.1941
- MIMS Australia. (2013). Anamorph. from Health Communication Network
- Mundt-Petersen, U., & Odin, P. (2017). Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms. International review of neurobiology, 134, 1019-1044. doi:https://dx.doi.org/10.1016/bs.irn.2017.05.036
- NHS TRUST. (2005). Apomorphine in the treatment of Parkinson’s disease. United Kingdom.
- Obering, C. D., Chen, J. J., & Swope, D. M. (2006). Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson’s disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 26(6), 840-852. doi:10.1592/phco.26.6.840
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. doi: 10.1136/bmj.n160
- Renoux, C., Dell’ Aniello, S., Khairy, P., Marras, C., Bugden, S., Turin, T. C., … Ernst, P. (2016). Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson’s disease. British Journal of Clinical Pharmacology, 82(2), 461-472. doi:10.1111/bcp.12964
- Sánchez-Ferro, A., Benito-León, J., & Gómez-Esteban, J. C. (2013). The management of orthostatic hypotension in Parkinson’s disease. frontiers in Neurology, 4(64), 1-11.
- Scorza, F. A., Scorza, C. A., & Ferraz, H. B. (2016). Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way. Clinics, 71(2), 59-61. doi:10.6061/clinics/2016(02)01
- Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AM-STAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7(1):1– 7. https://doi.org/10.1186/1471-2288-7-10
- Stocchi, F. (2009). Dopamine receptor agonists in the treatment of advanced Parkinson’s disease. Parkinsonism and Related Disorders, 15(4), S54-S57. doi:10.1016/S1353-8020(09)70836-3
- Tisch, S., & Bolitho, S. (2018). Apomorphine guidelines. Sydney
- Ul Haq, I., Lewitt, P. A., & Fernandez, H. H. (2007). Apomorphine therapy in Parkinson’s disease: a review. Expert opinion on pharmacotherapy, 8(16), 2799-2809.
- Wood, L. (2010). Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson’s Disease. Drugs & Aging, 27(4), 295-310. doi:10.2165/11318330-000000000-00000
- Zwar, N. A., Bunker, J. M., Reddel, H. K., Dennis, S. M., Middleton, S., van Schayck, O. C. P., … Xuan, W. (2016). Early intervention for chronic obstructive pulmonary disease by practice nurse and GP teams: a cluster randomized trial. Family Practice, 33 (6), 663-670. doi:10.1093/fampra/cmw077